trial

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia

NCTId NCT06107803
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 17 (actual)
Sponsored by Minerva Neurosciences
Primary completion 2024-01-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
17 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Sequential
Masking
None
Start
2023-10-13
Primary completion
2024-01-12
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
RoluperidoneOlanzapine

Sponsors

Minerva NeurosciencesLead Sponsor

Sites

3 total
Garden Grove, United StatesGaithersburg, United StatesMarlton, United States

Facts & assertions

4 sourced
Enrollment
17
Phase
PHASE1
Primary Completion Date
2024-01-12
Status
COMPLETED
relationships
The graph out of here
drug
Roluperidone
drug
Olanzapine
drug
lead_sponsor
Minerva Neurosciences
company
indication
Negative Symptoms in Schizophrenia
indication